Purchase of Nanobodies and epitope mapping for grant funded project

The Medicines and Healthcare products Regulatory Agency (MHRA), a central government public authority based in London, United Kingdom, has completed the procurement process for a project titled "Purchase of Nanobodies and epitope mapping for grant funded project." This contract, worth €80,000 with a gross amount of €96,000, covers laboratory services, laboratory reagents, and medical analysis services crucial to the healthcare and biopharmaceutical industry. The procurement method adopted was direct, without competition, due to the time-sensitive nature and specific expertise required for the project.

The contract was awarded to Proteogenix SAS, a large supplier based in Schiltigheim, France. The document was officially signed on 10th November 2025, and the contract period is from 11th November 2025 to 10th November 2026. This tender presents significant opportunities for businesses specialising in producing laboratory reagents and advanced medical analysis services.

Firms with capabilities in protein expression, especially those focusing on nanobody sequences, stand to gain substantially by positioning themselves as key suppliers in similar direct award contexts. The specificity and time constraints outlined in this contract highlight an environment in which nimble, experienced businesses in niche biopharmaceutical markets can excel and expand their market reach, particularly in serving public authorities engaged in high-priority, grant-financed projects.